Maria-victoria V. Mateos
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 369 publications
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026
High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 31, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2026
A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: June 16, 2026
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Redefining Early Relapse in Multiple Myeloma - Time to Change the Rules.
Journal: The New England journal of medicine
Published: May 29, 2026
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
Journal: Haematologica
Published: May 08, 2026
Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: April 27, 2026
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).
Journal: American journal of hematology
Published: April 09, 2026
Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 01, 2026
Last Updated: 09/26/2026